Funded Local Who is raising money in your own backyard?

Vancouver, British Columbia, June 18, 2009 — Burcon NutraScience Corporation (TSX –BU) (“Burcon” or the “Corporation”) is pleased to announce that it has completed its previously announced financing led by Paradigm Capital Inc., and including BMO Capital Markets and Haywood Securities Inc. (collectively, the “Agents”).

TELUS investment part of Teradici’s new US $17 million funding round

Burnaby, British Columbia April 7, 2009 – Teradici Corporation, the industry leader in delivering a true PC experience over standard IP networks, today announced completion of a US $17 million series C funding round for its PC-over-IP network-delivered computing technology. With network-delivered computing, users can work at inexpensive computer stations at any site, with all operating systems, applications, and data residing in central datacenters.

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced it has obtained a new Senior Secured Term Loan and Revolving Credit Facility. Wells Fargo Foothill, LLC is the sole arranger, administrative agent and lender for both the Term Loan and Revolving Credit Facility.

NxtGen Emission Controls Inc. announced today the closing of a $15.4 million USD Series B investment led by Altira Group LLC.

NxtGen is an emerging leader in syngas technology for diesel engine combustion optimization. NxtGen’s technology is making existing and new engines cleaner to meet global emission reduction regulations. It provides a platform for advanced emission and combustion technologies for multiple fuels, including diesel, biodiesel, natural gas and gasoline.

The announcement was made by Jeremy Holt, president and chief executive officer of NxtGen.

Brossard, QC, June 27, 2008– Railpower Technologies Corp. (TSX: P) (the “Corporation”) is pleased to announce that it has closed its previously announced $20 Million private placement with Teachers. The proceeds will be used to finance, among other things, construction of a manufacturing facility in Saint- Jean-sur-Richelieu.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC – Inimex Pharmaceuticals, Inc. is pleased to announce the closing of a US $22 Million Series B venture financing. Leading the round was Morningside Venture Investments Ltd., joined by additional new investors Roche Venture Fund, Switzerland, CA-based Astellas Venture Management LLC, the corporate venture capital arm of Astellas Pharma Inc. in Japan, and BC-based Advantage Life Science Fund II.

Vancouver BC, December 13, 2007 - Zeugma Systems Inc., a company developing a telecommunications system for next generation high speed broadband networks, today announced completion of its US$22.5 million Series B financing.

The financing was led by new investor Vertex Venture Capital. The syndicate members include returning investors Granite Ventures, Ventures West, Yaletown Venture Partners, GrowthWorks Capital Ltd. and BDC Venture Capital, as well as new investors GTD Capital and BC Advantage Funds.

Calgary, AB, November 8, 2007 - 1322256 Alberta Ltd. (the “Company”; formerly Inex Pharmaceuticals Corporation), is pleased to announce the closing of a non-brokered private placement consisting of 222,727,273 common shares for gross proceeds of $12,250,000 at a price of $0.055 per share (the "Offering").

Net proceeds from the Offering will be used to fund business development activities as the Company seeks new opportunities to deploy its capital. Officers and directors of the Company participated in the Offering for $4,287,500 (77,954,545 shares).

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 24, 2007) - Inflazyme Pharmaceuticals Ltd. (TSX:IZP) and Biolipox AB, a private Swedish pharmaceutical company, today announced that they have entered into a definitive asset purchase agreement whereby Biolipox will acquire the majority of Inflazyme's assets for potential gross proceeds of up to $11 million plus a potential royalty payment. The assets include Inflazyme's research and development programs on the LSAIDs(TM), the PDE inhibitors and the Protein Therapeutics Technology.